Dr. Fabian Müller


Lehrstuhl für Klinische Pharmakologie und Klinische Toxikologie

Publikationen (Download BibTeX)

Go to first page Go to previous page 1 von 2 Go to next page Go to last page

Stopfer, P., Giessmann, T., Hohl, K., Hutzel, S., Schmidt, S., Gansser, D.,... Müller, F. (2018). Optimization of a drug transporter probe cocktail: potential screening tool for transporter-mediated drug-drug interactions. British Journal of Clinical Pharmacology, 84(9), 1941-1949. https://dx.doi.org/10.1111/bcp.13609
Plank-Kiegele, B., Bürkle, T., Müller, F., Patapovas, A., Sonst, A., Pfistermeister, B.,... Maas, R. (2017). Data requirements for the correct identification of medication errors and adverse drug events in patients presenting at an emergency department. Methods of Information in Medicine, 56(4), 276-282. https://dx.doi.org/10.3414/ME16-01-0126
Reznicek, J., Ceckova, M., Cerveny, L., Müller, F., & Staud, F. (2017). Emtricitabine is a substrate of MATE1 but not of OCT1, OCT2, P-gp, BCRP or MRP2 transporters. Xenobiotica, 47(1), 77-85. https://dx.doi.org/10.3109/00498254.2016.1158886
Ceckova, M., Reznicek, J., Ptackova, Z., Cerveny, L., Müller, F., Kacerovsky, M.,... Staud, F. (2016). Role of ABC and Solute Carrier Transporters in the Placental Transport of Lamivudine. Antimicrobial Agents and Chemotherapy, 60(9), 5563-72. https://dx.doi.org/10.1128/AAC.00648-16
Misaka, S., Knop, J., Singer, K., Hoier, E., Keiser, M., Müller, F.,... Fromm, M. (2016). The Nonmetabolized β-Blocker Nadolol Is a Substrate of OCT1, OCT2, MATE1, MATE2-K, and P-Glycoprotein, but Not of OATP1B1 and OATP1B3. Molecular Pharmaceutics, 13(2), 512-9. https://dx.doi.org/10.1021/acs.molpharmaceut.5b00733
Meier, F., Maas, R., Sonst, A., Patapovas, A., Müller, F., Plank-Kiegele, B.,... Dormann, H. (2015). Adverse drug events in patients admitted to an emergency department: an analysis of direct costs. Pharmacoepidemiology and Drug Safety, 24(2), 176-186. https://dx.doi.org/10.1002/pds.3663
Knop, J., Misaka, S., Singer, K., Hoier, E., Müller, F., Gläser, H.,... Fromm, M. (2015). Inhibitory Effects of Green Tea and (-)-Epigallocatechin Gallate on Transport by OATP1B1, OATP1B3, OCT1, OCT2, MATE1, MATE2-K and P-Glycoprotein. PLoS ONE, 10(10), e0139370. https://dx.doi.org/10.1371/journal.pone.0139370
Knop, J., Hoier, E., Ebner, T., Fromm, M., & Müller, F. (2015). Renal tubular secretion of pramipexole. European Journal of Pharmaceutical Sciences, 79, 73-8. https://dx.doi.org/10.1016/j.ejps.2015.09.004
Müller, F., Dormann, H., Pfistermeister, B., Sonst, A., Patapovas, A., Vogler, R.,... Maas, R. (2014). Application of the Pareto principle to identify and address drug-therapy safety issues. European Journal of Clinical Pharmacology, 70(6), 727-36. https://dx.doi.org/10.1007/s00228-014-1665-2
Misaka, S., Yatabe, J., Müller, F., Takano, K., Kawabe, K., Gläser, H.,... Kimura, J. (2014). Green tea ingestion greatly reduces plasma concentrations of nadolol in healthy subjects. Clinical Pharmacology & Therapeutics, 95(4), 432-8. https://dx.doi.org/10.1038/clpt.2013.241

Zuletzt aktualisiert 2016-05-05 um 05:06